Literature DB >> 15939314

Inhibition of in vitro neutrophil migration through a bilayer of endothelial and epithelial cells using beta2-agonists: concomitant effects on IL-8 and elastase secretion and impact of glucocorticosteroids.

A M Sadowska1, B Manuel-y-Keenoy, W A De Backer.   

Abstract

BACKGROUND: Beta2-agonists and glucocorticosteroids are two common treatments for COPD and they are often used in combination. Glucocorticosteroids mediate the anti-inflammatory response through the glucocorticosteroid receptors (GRs). Beta2-agonists are potent bronchodilators but they can have some anti-inflammatory properties by elevating the level of intracellular cAMP. In this study we aimed to investigate the anti-inflammatory effect of combination therapy in vitro.
METHODS: Neutrophils or the bilayer of endothelial and epithelial cells were preincubated with salbutamol, budesonide or budesonide followed by salbutamol. FMLP-induced IL-8, elastase release and neutrophil migration through the bilayer was measured.
RESULTS: Salbutamol at concentrations of 10(-4), 10(-5) and 10(-9) M inhibited IL-8, elastase release and migration of neutrophils in an inverse bell-shaped concentration-response manner. When given after budesonide (10(-9) and 10(-8)M), the inhibitory effect on migration was additive. This additive effect was not observed for elastase and IL-8 release.
CONCLUSIONS: Salbutamol inhibits neutrophil migration and IL-8 and elastase release in a concentration-dependent manner. Preincubation with low concentration of budesonide enhanced the inhibition of migration achieved by low concentrations of salbutamol.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939314     DOI: 10.1016/j.pupt.2005.01.006

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  1 in total

1.  Activation of granulocytes by direct interaction with dendritic cells.

Authors:  M Tsuda; M Inaba; Y Sakaguchi; J Fukui; Y Ueda; M Omae; Y Ando; H Mukaide; K Guo; T Yabuki; T Nakatani; S Ikehara
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.